Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
118.56%
Operating Margin
74.04%
Net Margin
103.06%
Efficiency Metrics
Revenue per Expense Ratio
-37,260,845.0
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
74.04%
Income Tax Rate
0.00%
EPS
-1.0100000000
Balance Sheet Analysis
Current Ratio
9.26
Cash Ratio
5.01
Working Capital
$7.50M
Debt to Equity
0.33
Debt to Assets
23.02%
Equity Ratio
69.86%
Cash Flow Analysis
Operating Cash Flow Ratio
-213.14%
Free Cash Flow Ratio
-213.14%
CapEx to Revenue
0.00%
Dividends Paid
$47.22M
Stock Buybacks
$5.00M
Total Shareholder Returns
$52.22M
Cash Position Change
-11.47%
Key Takeaways (2023 FY)
Revenue declined by 198.56276458684%, indicating potential market challenges
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-198.56%
Net Income
-204.11%
EPS
-206.06%
Operating Income
-242.17%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
0.37%
Operating Cash Flow
10.87%
Free Cash Flow
10.87%
Balance Sheet Health
Assets
-17.89%
Debt
-19.35%
Book Value per Share
-18.56%
Inventory
-28.16%
Shareholder Returns
Dividends per Share
-8.64%
Shares Outstanding
0.17%
Long Term Trends
3Y Revenue/Share
65.87%
5Y Revenue/Share
-28.68%
3Y Dividend/Share
-11.62%
5Y Dividend/Share
-11.66%